Conference Call Participants
Corey Davis – Lifesci Advisors, LLC
Yasmeen Rahimi – Piper Sandler & Co., Research Division
Evan Seigerman – BMO Capital Markets Equity Research
Seamus Fernandez – Guggenheim Securities, LLC, Research Division
David Risinger – Leerink Partners LLC, Research Division
Terence Flynn – Morgan Stanley, Research Division
Prakhar Agrawal – Cantor Fitzgerald & Co., Research Division
Samantha Semenkow – Citigroup Inc., Research Division
Jonathan Wolleben – Citizens JMP Securities, LLC, Research Division
Jiale Song – Jefferies LLC, Research Division
Tsan-Yu Hsieh – William Blair & Company L.L.C., Research Division
Corinne Jenkins – Goldman Sachs Group, Inc., Research Division
Jayed Momin – Stifel, Nicolaus & Company, Incorporated, Research Division
Hardik Parikh – JPMorgan Chase & Co, Research Division
Presentation
Operator
Good morning, and welcome to the Structure Therapeutics Conference Call. [Operator Instructions] Please be advised that this conference call is being recorded. I would now like to turn the call over to Corey Davis of LifeSci Advisors.
Corey Davis
Lifesci Advisors, LLC
Thank you, Dan, and good morning, everyone. Earlier today, we issued a press release providing top line results from the ACCESS II clinical program for aleniglipron, our oral small molecule GLP-1 receptor agonist. A copy of this release and the presentation accompanying this call are available on the Investor Relations section of the Structure Therapeutics website.
I’d like to remind everyone that some of the statements we’ll make on this call and information presented in the slide deck may include forward-looking statements, which you see here. These forward-looking statements involve a number of risks and uncertainties that could cause actual results to differ materially. Please refer to this slide as well as our SEC